MTOR and graft versus host disease: Those factors are: graft-versus-host disease (GVHD) [94], [95], [96], [97], [98]; calcineurin inhibitors (CNI) [90,94]; mammalian target of rapamycin inhibitors (mTORI) [95]; disseminated infections [91,98,99]; myeloablative and conditioning regimens, especially those with a high dose of busulfan and total-body irradiation (TBI) [88,95,96]; and HLA mismatch [90,96].